Paul, the four-legged therapist
The History of Dialysis
’Remain true to your ideals’
Serving patients in Swaziland
Using protons to take on cancer
A little heart at the center of a complex surgery
On duty in disaster zones
More ‘Quality of Life’ in clinics
Ready to help the littlest ones
"I want to help others, so they won’t give up"
A polyclinic in Ghana
From a local pharmacy to a global corporation
Group Outlook 2018
In 2018, we expect to increase Group sales1,2 by 5% to 8% in constant currency. We project Group net income1,3,4 to increase by 6% to 9% in constant currency.
Fresenius Group Overview
- The Health Care Group
-
Stories
-
![]()
Paul, the four-legged therapist
-
![]()
The History of Dialysis
-
![]()
’Remain true to your ideals’
-
![]()
Serving patients in Swaziland
-
![]()
Using protons to take on cancer
-
![]()
A little heart at the center of a complex surgery
-
![]()
On duty in disaster zones
-
![]()
More ‘Quality of Life’ in clinics
-
![]()
Ready to help the littlest ones
-
![]()
"I want to help others, so they won’t give up"
-
![]()
A polyclinic in Ghana
-
![]()
From a local pharmacy to a global corporation
-
- Investors
-
Media
![]()
Contact
Matthias Link
Vice President Corporate Communications
T: +49 (0) 6172 608-2872
matthias.link@fresenius.com - Careers
Outlook
- Investors
- Strategy & Outlook
- Outlook
-
Share Price
Data is delayed by 15 minutes.
Share Price Information -
Related Links
-
Library
-
Event
October 30, 2018 - 02:00 PM | Bad Homburg, Germany
Conference Call Q3 2018, Fresenius
-
FAQ
| Targets 20181 | Fiscal year 2017 | |
| Fresenius Group | ||
| Sales growth (in constant currency) | 5% – 8% | € 33,400 million2 |
|
Net income3 growth |
6% – 9%4 | € 1,816 million5 |
| Net income3 growth (in constant currency), excluding Biosimilars |
~10% – 13%6 |
€ 1,859 million7 |
| Fresenius Medical Care | ||
|
Sales growth (in constant currency) |
5% – 7%8 |
€ 17,298 million8 |
| Net income14 growth | 13% – 15%9 | € 1,280 million |
| Fresenius Kabi | ||
| Sales growth (organic) | 4% – 7% | € 6,358 million |
| EBIT growth10 (in constant currency) | -3% – -6% | € 1,177 million |
| EBIT growth11 (in constant currency), excluding Biosimilars |
~2% – 5% |
€ 1,237 million |
| Fresenius Helios | ||
| Sales growth (organic) | 3% – 6%12 | € 8,668 million13 |
| EBIT growth |
7% – 10% | € 1,052 million13 |
| Fresenius Vamed | ||
| Sales growth (organic) | 5% – 10% | € 1,228 million |
| EBIT growth | 5% – 10% | € 76 million |
- 1 Excluding effects of the Akorn, NxStage and Sound Physicians transactions
- 2 Adjusted for IFRS 15 (€ -486 million at Fresenius Medical Care)
- 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
- 4 Before special items (before transaction-related effects); including expenditures for further development of biosimilars business (€ 43 million after tax in FY / 17 and ~€ 120 million after tax in FY / 18)
- 5 Before special items (before transaction-related effects, before book gain from U.S. tax reform, before FCPA provision)
- 6 Before special items (before transaction-related effects); excluding expenditures for further development of biosimilars business (€ 43 million after tax in FY / 17 and ~€ 120 million after tax in FY / 18)
- 7 Adjusted net income: before transaction-related effects, before expenditures for further development of biosimilars business, before book gain from U.S. tax reform, before FCPA provision
- 8 Reported sales 2017 of € 17,784 million, adjusted for IFRS 15 (€ -486 million)
- 9 2018 including recurring benefits from U.S. tax reform and adjusted for the re-valuation of Sound Physicians’ share-based payment program caused by its announced divestiture
- 10 Before special items (before transaction-related effects); including expenditures for further development of biosimilars business (€ 60 million in FY / 17 and expected expenditures of ~€ 160 million in FY / 18)
- 11 Before special items (before transaction-related effects); excluding expenditures for further development of biosimilars business (€ 60 million in FY / 17 and expected expenditures of ~€ 160 million in FY / 18)
- 12 Organic growth reflects 11 months contribution of Helios Spain
- 13 Helios Spain consolidated for 11 months
- 14 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
- As of May, 2018
Contact us
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com
Contact
